Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Nexalin Technology Inc (NXLIW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/31/2025: NXLIW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 15.71% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 03/31/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 36332 | Beta 4.39 | 52 Weeks Range 0.05 - 0.78 | Updated Date 03/25/2025 |
52 Weeks Range 0.05 - 0.78 | Updated Date 03/25/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -10579.48% |
Management Effectiveness
Return on Assets (TTM) -123.41% | Return on Equity (TTM) -221.05% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 10812305 |
Shares Outstanding - | Shares Floating 10812305 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Nexalin Technology Inc
Company Overview
History and Background
Nexalin Technology Inc. is a medical device company focused on developing and commercializing neurostimulation devices for mental health disorders. Founded in 2010, it has focused on non-invasive brain stimulation technology.
Core Business Areas
- Neurostimulation Devices: Development and commercialization of non-invasive neurostimulation devices designed to treat anxiety, depression, and insomnia.
Leadership and Structure
Mark Swingle is the CEO. The company operates with a core team focused on research and development, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- Gen-1 & Gen-2 Nexalin Devices: Nexalin's neurostimulation devices target specific brain structures to modulate neural activity. These devices are intended to alleviate symptoms of anxiety, depression, and insomnia. Limited market share data is available, but competition includes transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) devices from companies like Neuronetics (STIM) and MagVenture.
Market Dynamics
Industry Overview
The neurostimulation device market is growing, driven by increasing prevalence of mental health disorders and demand for non-pharmacological treatment options.
Positioning
Nexalin is a player in the non-invasive neurostimulation market, seeking to differentiate itself through device design and clinical evidence.
Total Addressable Market (TAM)
The TAM for neurostimulation devices for mental health is estimated to be several billion dollars. Nexalin is positioned to capture a portion of this market with successful clinical trials and commercialization.
Upturn SWOT Analysis
Strengths
- Proprietary neurostimulation technology
- Potential for non-pharmacological treatment option
- Focus on mental health disorders
Weaknesses
- Limited commercialization experience
- Small market capitalization
- Dependence on regulatory approvals
- Requires more clinical trials to support efficacy
Opportunities
- Expanding market for mental health treatments
- Potential partnerships with healthcare providers
- Positive clinical trial results
- New device developments
Threats
- Competition from established neurostimulation companies
- Regulatory hurdles
- Reimbursement challenges
- Adverse events or lack of efficacy in clinical trials
Competitors and Market Share
Key Competitors
- STIM
- NEU
Competitive Landscape
Nexalin faces competition from established players with more resources. Its success depends on differentiating its technology and demonstrating clinical efficacy.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth has been limited to date, with the company primarily focused on research and development.
Future Projections: Future growth is dependent on successful clinical trials, regulatory approvals, and commercialization. Analyst projections are speculative at this stage.
Recent Initiatives: Recent initiatives include clinical trials, regulatory submissions, and seeking commercial partnerships.
Summary
Nexalin Technology Inc. is a speculative investment in the neurostimulation space, heavily dependent on clinical trial results and regulatory approvals. Its potential lies in its proprietary technology for treating mental health disorders, but it faces challenges from established competitors and financial constraints. The company needs to demonstrate clear clinical efficacy and secure commercial partnerships to achieve sustainable growth and the long term success of the business. Securing reimbursements for medical procedures performed with their devices will be a key aspect as well.
Similar Companies
- STIM
- NEU
Sources and Disclaimers
Data Sources:
- Company Filings
- Press Releases
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on your own research and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nexalin Technology Inc
Exchange NASDAQ | Headquaters Houston, TX, United States | ||
IPO Launch date 2022-09-16 | President, CEO, CFO & Director Mr. Mark White | ||
Sector Healthcare | Industry Medical Devices | Full time employees 6 | Website https://www.nexalin.com |
Full time employees 6 | Website https://www.nexalin.com | ||
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.